Purdue Pharma Canada is pleased to announce the appointment of Craig Landau, MD to the position of President and CEO at the beginning of September 2013. Dr. Landau will be taking over from Dr. Cornelia Hentzsch, who successfully led Purdue Canada through a challenging transition from OxyContin® to OxyNEO®. Dr. Hentzsch will become a full-time advisor to the Board of Directors and continue her role as Regional Director for Australia/New Zealand.
Dr. Landau entered the pharmaceutical industry in 1997 and has spent the last 14 years at Purdue Pharma (U.S.), headquartered in Stamford, Connecticut. In his most recent role as Chief Medical Officer and Vice President of R&D Innovation, Clinical and Medical Affairs, he led a number of successful clinical development initiatives resulting in analgesic product registrations in the U.S., Europe, and other regions. Through an R&D Innovation function, Dr. Landau has been responsible for pursuing non-drug based technologies and biomarkers intended to bring additional objectivity to the diagnosis and management of pain and the pain patient. Through April 2013, he played a lead role in the development and approval of reformulated OxyContin, a product recently determined by the U.S. Food and Drug Administration to possess abuse deterrent characteristics.
Dr. Landau earned his BSc degree in Physiology and Anatomy from Cornell University, and his MD degree from Mount Sinai School of Medicine. He completed his Anesthesiology residency at Yale University, with specialty training in chronic pain management, obstetric and peripheral vascular anesthesia. A U.S. Army Veteran, in 2004 he completed a distinguished 12-year career in the U.S. Army Medical Corps, Reserve Component, providing clinical anesthesia and pain management care to soldiers at a combat support hospital in support of American forces in Iraq and Afghanistan.